肺がん治療の世界市場

肺がん治療薬の世界市場は、2025年の325億ドルから成長し、2030年末までに495億ドルに達すると予測されており、2025年から2030年の予測期間における年平均成長率（CAGR）は8.8%となる見込みです。

レポートの内容

• 86のデータ表と55の追加表
• 肺がん治療薬の世界市場の概要
• 2022年から2025年までの過去の収益データと2030年までの予測を含む、世界市場動向の詳細な分析。この分析には、2030年までの年平均成長率（CAGR）の予測が含まれます。
• 肺がん治療薬に特化した現在の市場規模と収益成長見通しの評価。タイプ別、治療薬別、地域別の市場シェア分析も併せて掲載。
• 肺がん治療薬市場における現在および将来の需要分析。競争環境、市場規制、償還慣行の詳細な分析も併せて掲載。
• 市場成長に影響を与える要因、課題、機会の分析
• 進化する技術、現在および将来の市場潜在力、研究開発活動、臨床試験、成長戦略、新製品パイプライン、規制枠組みと償還シナリオ、市場のESG動向に関する分析
• 業界主要企業の市場シェア分析。各社の研究優先事項、製品情報も併せて掲載。ポートフォリオ、グローバルランキング、企業間の競争環境
• アストラゼネカ、メルク、F・ホフマン・ラ・ロシュ、ノバルティス、ブリストル・マイヤーズ スクイブ、ファイザーなど、業界主要企業のプロフィール

Report Highlights

The global market for lung cancer therapeutics is expected to grow from $32.5 billion in 2025 and is projected to reach $49.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.8% during the forecast period of 2025 to 2030.

Report Includes

• 86 data tables and 55 additional tables
• An overview of the global market for lung cancer therapeutics
• In-depth analysis of global market trends, featuring historical revenue data for 2022-2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
• Evaluation of the current market size and revenue growth prospects specific to the lung cancer therapeutics, accompanied by a market share analysis by type, therapeutics, and region
• Analysis of current and future demand in the lung cancer therapeutics market, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
• Analysis of drivers, challenges, and opportunities affecting market growth
• Coverage of evolving technologies, the current and future market potential, R&D activities, clinical trials, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
• Market share analysis of the key market participants in the industry, along with their research priorities, product portfolios, global rankings and company competitive landscape
• Profiles of major companies within the industry, including AstraZeneca, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Co., and Pfizer Inc.

Report Scope

This report will provide detailed information on lung cancer therapeutics. This report analyzes the market trends for lung cancer therapeutics, providing data for 2024, estimates for 2025, projections of compound annual growth rates (CAGRs) through 2030 (forecast period: 2025–2030) and regional markets for lung cancer therapeutics. This report will highlight the current and future market potential of lung cancer therapeutics, providing a detailed analysis of the competitive environment. The report will cover regulatory scenarios, drivers, restraints and opportunities, as well as market projections for 2030 and the market share for key market players.

In this report, the market is segmented by cancer type into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). By therapeutic type, the market is segmented into targeted therapy, chemotherapy and immunotherapy.

The market has been segmented into five regions: North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America. This report will also provide detailed analyses of major countries, including the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia and India. For market estimates, data will be provided for 2024, given the base year, along with data for 2025 and a forecast value for 2030.

The report aims to:

• Analyze types of lung cancer therapeutics.
• Analyze global market size and segments.
• Understand market constraints and drivers.
• Provide detailed market forecasts for 2030.
• Assess market shares, competitiveness and industry structure.
• Identify potential long-term impacts on the lung cancer therapeutics market.

Table of Contents

Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Overview
Macroeconomic Factors Analysis
Impact of U.S. Tariffs on the Pharmaceutical Industry
Healthcare Expenditure
Geopolitical Risks, Trade Wars and Supply Chain Disruptions
Impact of Global Economic Growth (GDP) on the Pharma Sector
Porter’s Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Threat of Substitutes
Competitiveness in the Industry
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Rising Lung Cancer Cases
Increasing Innovation in Lung Cancer Therapeutics
Increasing R&D Spending by Market Players
Rise in Government Funding and Pharmaceutical R&D Spending
Market Restraints
Rising Generic Competition and Patent Expiration
Shortage of Oncology Professionals
Available Low-Priced Chemotherapeutics Limiting Growth of Advanced Therapies
Market Opportunities
Increasing Demand for Novel Therapies
Emerging Markets
Increasing Lung Cancer Incidence Among Non-Smokers
Chapter 4 Regulatory Landscape
Overview
U.S.
Europe
Asia-Pacific
Chapter 5 Emerging Technologies and Pipeline Analysis
Overview
Artificial Intelligence
Immunotherapies and Cell Therapy
Emergent Biomarkers
Clinical Trial Analysis
Clinical Trials Analysis by Type of Study
Clinical Trials Analysis by Status
Clinical Trials Analysis by Phase
Key Takeaways
Patent Analysis
Key Takeaways
Chapter 6 Market Segment Analysis
Segmentation Breakdown
Global Market for Lung Cancer Therapeutics, by Cancer Type
Key Takeaways
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Global Market for Lung Cancer Therapeutics, by Therapeutic
Key Takeaways
Targeted Therapy
Chemotherapy
Immunotherapy
Geographic Breakdown
Global Market for Lung Cancer Therapeutics, by Region
Key Takeaways
North America
Europe
Asia-Pacific
Middle East and Africa
South America
Chapter 7 Competitive Intelligence
Key Takeaways
Competitive Landscape
Company Share Analysis
Strategic Analysis
Chapter 8 Sustainability in the Global Market for Lung Cancer Therapeutics: An ESG Perspective
Introduction to ESG
Sustainability in the Lung Cancer Therapeutics Market
ESG Perspective
Environmental Impact
Social Impact
Governance Impact
ESG Risk Ratings
Conclusion
Chapter 9 Appendix
Methodology
Abbreviations
Sources
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
JAZZ PHARMACEUTICALS INC.
JOHNSON & JOHNSON
LILLY USA LLC.
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
TAKEDA PHARMACEUTICAL CO. LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Emerging Players/Market Disruptors

List of Tables

Summary Table : Global Market for Lung Cancer Therapeutics, by Region, Through 2030
Table 1 : Health Expenditure, by Country, 2021–2023
Table 2 : Lung Cancer Statistics, by Region 2022 and 2023
Table 3 : NCI Funding, by Mechanism, 2020–2024
Table 4 : Selected Approved Biosimilars in the Market
Table 5 : Clinical Trials in Lung Cancer Therapeutics, by Type of Study, as of November 2025
Table 6 : Clinical Trials in Lung Cancer Therapeutics, by Status, as of November 2025
Table 7 : Clinical Trials in Lung Cancer Therapeutics, by Phase, as of November 2025
Table 8 : List of Selected Lung Cancer Therapeutics Clinical Trial Studies, 2025
Table 9 : List of Selected Recently Granted Patents Related to Lung Cancer Therapeutics, 2024-2025
Table 10 : Global Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 11 : Global Market for NSCLC in Lung Cancer Therapeutics, by Region, Through 2030
Table 12 : Global Market for SCLC in Lung Cancer Therapeutics, by Region, Through 2030
Table 13 : Global Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 14 : Selected Approved Targeted Therapies in the Lung Cancer Therapeutics Market
Table 15 : Global Market for Targeted Therapy in Lung Cancer Therapeutics, by Region, Through 2030
Table 16 : Selected Approved Chemotherapies in the Lung Cancer Therapeutics Market
Table 17 : Global Market for Chemotherapy in Lung Cancer Therapeutics, by Region, Through 2030
Table 18 : Selected Approved Immunotherapies in the Lung Cancer Therapeutics Market
Table 19 : Global Market for Immunotherapy in Lung Cancer Therapeutics, by Region, Through 2030
Table 20 : Global Market for Lung Cancer Therapeutics, by Region, Through 2030
Table 21 : North American Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 22 : North American Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 23 : North American Market for Lung Cancer Therapeutics, by Country, Through 2030
Table 24 : U.S. Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 25 : U.S. Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 26 : Canadian Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 27 : Canadian Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 28 : Mexican Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 29 : Mexican Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 30 : European Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 31 : European Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 32 : European Market for Lung Cancer Therapeutics, by Country, Through 2030
Table 33 : German Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 34 : German Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 35 : U.K. Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 36 : U.K. Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 37 : French Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 38 : French Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 39 : Italian Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 40 : Italian Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 41 : Spanish Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 42 : Spanish Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 43 : Rest of Europe Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 44 : Rest of Europe Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 45 : Lung Cancer Cases in Asia-Pacific, by Region, 2022
Table 46 : Asia-Pacific Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 47 : Asia-Pacific Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 48 : Asia-Pacific Market for Lung Cancer Therapeutics, by Country, Through 2030
Table 49 : Chinese Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 50 : Chinese Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 51 : Japanese Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 52 : Japanese Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 53 : Indian Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 54 : Indian Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 55 : South Korean Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 56 : South Korean Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 57 : Australian Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 58 : Australian Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 59 : Rest of Asia-Pacific Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 60 : Rest of Asia-Pacific Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 61 : MEA Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 62 : MEA Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 63 : MEA Market for Lung Cancer Therapeutics, by Sub-Region, Through 2030
Table 64 : Middle Eastern Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 65 : Middle Eastern Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 66 : African Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 67 : African Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 68 : South American Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 69 : South American Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 70 : South American Market for Lung Cancer Therapeutics, by Country, Through 2030
Table 71 : Brazilian Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 72 : Brazilian Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 73 : Argentine Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 74 : Argentine Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 75 : Rest of South America Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 76 : Rest of South America Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 77 : Key Strategic Initiatives in Lung Cancer Therapeutics Market, 2024-2025
Table 78 : Key Focus Areas in ESG Metrics
Table 79 : ESG Rankings for Leading Companies in Lung Cancer Therapeutics, 2025*
Table 80 : Abbreviations Used in this Report
Table 81 : Report Sources
Table 82 : AbbVie Inc.: Company Snapshot
Table 83 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 84 : AbbVie Inc.: Product Portfolio
Table 85 : AbbVie Inc.: News/Key Developments, 2025
Table 86 : Amgen Inc.: Company Snapshot
Table 87 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 88 : Amgen Inc.: Product Portfolio
Table 89 : Amgen Inc.: News/Key Developments, 2023-2025
Table 90 : AstraZeneca: Company Snapshot
Table 91 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 92 : AstraZeneca: Product Portfolio
Table 93 : AstraZeneca: News/Recent Developments, 2022-2025
Table 94 : Boehringer Ingelheim International GmbH: Company Snapshot
Table 95 : Boehringer Ingelheim International GmbH: Financial Performance, FY 2023 and 2024
Table 96 : Boehringer Ingelheim International GmbH: Product Portfolio
Table 97 : Boehringer Ingelheim International GmbH: News/Key Developments, 2025
Table 98 : Bristol-Myers Squibb Co.: Company Snapshot
Table 99 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 100 : Bristol-Myers Squibb Co.: Product Portfolio
Table 101 : Bristol-Myers Squibb Co.: News/Key Developments, 2023-2025
Table 102 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 103 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 104 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 105 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2025
Table 106 : Jazz Pharmaceuticals Inc.: Company Snapshot
Table 107 : Jazz Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 108 : Jazz Pharmaceuticals Inc.: Product Portfolio
Table 109 : Jazz Pharmaceuticals Inc.: News/Key Developments, 2025
Table 110 : Johnson & Johnson: Company Snapshot
Table 111 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
Table 112 : Johnson & Johnson Services Inc.: Product Portfolio
Table 113 : Johnson & Johnson Services Inc.: News/Key Developments, 2022−2025
Table 114 : Lilly USA LLC.: Company Snapshot
Table 115 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 116 : Lilly USA LLC.: Product Portfolio
Table 117 : Lilly USA LLC.: News/Key Development, 2022-2025
Table 118 : Merck & Co. Inc.: Company Snapshot
Table 119 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 120 : Merck & Co. Inc.: Product Portfolio
Table 121 : Merck & Co. Inc.: News/Key Developments, 2022–2025
Table 122 : Novartis AG: Company Snapshot
Table 123 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 124 : Novartis AG: Product Portfolio
Table 125 : Novartis AG: News/Key Developments, 2022
Table 126 : Pfizer Inc.: Company Snapshot
Table 127 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 128 : Pfizer Inc.: Product Portfolio
Table 129 : Pfizer Inc.: News/Key Developments, 2023-2025
Table 130 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 131 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 132 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 133 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2025
Table 134 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 135 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2023 and 2024
Table 136 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 137 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 138 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
Table 139 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 140 : A Few Emerging Players in the Lung Cancer Therapeutics Market

List of Figures

Summary Figure : Global Market Shares of Lung Cancer Therapeutics, by Region, 2024
Figure 1 : Porter’s Five Forces Analysis of the Lung Cancer Therapeutics Market
Figure 2 : Market Dynamics of Lung Cancer Therapeutics
Figure 3 : Global Shares of Five-Year Prevalence Cases of Lung Cancer, by Region, 2022
Figure 4 : Global Market Shares of Companies’ R&D Expenditure, by Function, 2022
Figure 5 : Global Pharmaceutical R&D Spending and Growth, 2020–2026
Figure 6 : Global Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 7 : Global Market Shares of NSCLC in Lung Cancer Therapeutics, by Region, 2024
Figure 8 : Global Market Shares of SCLC in Lung Cancer Therapeutics, by Region, 2024
Figure 9 : Global Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 10 : Global Market Shares of Targeted Therapy in Lung Cancer Therapeutics, by Region, 2024
Figure 11 : Global Market Shares of Chemotherapy in Lung Cancer Therapeutics, by Region, 2024
Figure 12 : Global Market Shares of Immunotherapy in Lung Cancer Therapeutics, by Region, 2024
Figure 13 : Global Market Shares of Lung Cancer Therapeutics, by Region, 2024
Figure 14 : North American Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 15 : North American Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 16 : North American Market Shares of Lung Cancer Therapeutics, by Country, 2024
Figure 17 : U.S. Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 18 : U.S. Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 19 : Canadian Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 20 : Canadian Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 21 : Mexican Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 22 : Mexican Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 23 : European Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 24 : European Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 25 : European Market Shares of Lung Cancer Therapeutics, by Country, 2024
Figure 26 : German Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 27 : German Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 28 : U.K. Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 29 : U.K. Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 30 : French Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 31 : French Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 32 : Italian Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 33 : Italian Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 34 : Spanish Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 35 : Spanish Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 36 : Rest of Europe Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 37 : Rest of Europe Market Shares of Lung Cancer Therapeutics, by Therapeutics, 2024
Figure 38 : Asia-Pacific Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 39 : Asia-Pacific Market Shares of Lung Cancer Therapeutics, by Therapeutics, 2024
Figure 40 : Asia-Pacific Market Shares of Lung Cancer Therapeutics, by Country, 2024
Figure 41 : Chinese Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 42 : Chinese Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 43 : Japanese Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 44 : Japanese Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 45 : Indian Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 46 : Indian Market Shares of Lung Cancer Therapeutics, by Therapeutics, 2024
Figure 47 : South Korean Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 48 : South Korean Market Shares of Lung Cancer Therapeutics, by Therapeutics, 2024
Figure 49 : Australian Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 50 : Australian Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 51 : Rest of Asia-Pacific Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 52 : Rest of Asia-Pacific Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 53 : MEA Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 54 : MEA Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 55 : MEA Market Shares of Lung Cancer Therapeutics, by Sub-Region, 2024
Figure 56 : Middle Eastern Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 57 : Middle Eastern Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 58 : African Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 59 : African Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 60 : South American Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 61 : South American Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 62 : South American Market Shares of Lung Cancer Therapeutics, by Country, 2024
Figure 63 : Brazilian Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 64 : Brazilian Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 65 : Argentine Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 66 : Argentine Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 67 : Rest of South America Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 68 : Rest of South America Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 69 : Top 10 Blockbuster Lung Cancer Therapeutics, by Sales Revenue, 2023-2024
Figure 70 : Global Market Shares of Lung Cancer Therapeutics, by Company, 2024
Figure 71 : Pillars of ESG
Figure 72 : Advantages of ESG for Companies
Figure 73 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 74 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 75 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 76 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 77 : AstraZeneca: Revenue Shares, by Business Unit, FY 2024
Figure 78 : AstraZeneca: Revenue Shares, by Region/Country, FY 2024
Figure 79 : Boehringer Ingelheim International GmbH: Revenue Shares, by Business Unit, FY 2024
Figure 80 : Boehringer Ingelheim International GmbH: Revenue Shares, by Region, FY 2024
Figure 81 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
Figure 82 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
Figure 83 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 84 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2024
Figure 85 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 86 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 87 : Johnson & Johnson: Revenue Shares, by Business Unit, FY 2024
Figure 88 : Johnson & Johnson: Revenue Shares, by Country/Region, FY 2024
Figure 89 : Lilly USA LLC.: Revenue Shares, by Business Unit, FY 2024
Figure 90 : Lilly USA LLC.: Revenue Shares, by Country/Region, FY 2024
Figure 91 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 92 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 93 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
Figure 94 : Novartis AG: Revenue Shares, by Country/Region, FY 2024
Figure 95 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 96 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 97 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 98 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 99 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 100 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Country/Region, FY 2024
Figure 101 : Teva Pharmaceutical Industries Ltd.: Revenue Shares, by Country/Region, FY 2024